1224944-69-7Relevant academic research and scientific papers
PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
-
Page/Page column 85, (2012/02/03)
The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
-
Page/Page column 82, (2011/02/24)
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical
